L. Sierra

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.

Robin L. Jones, G. Demetri, O. Mir, 2020, The Lancet. Oncology.

p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma

K. Rajapakshe, C. Coarfa, J. Yustein, 2021, Oncogene.

Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.

N. Shukla, C. Wetmore, D. Hargrave, 2020 .

Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma

C. Coarfa, J. Yustein, R. Shuck, 2020, Cancer Research.

Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).

Robin L. Jones, G. Demetri, T. Chen, 2019, Journal of Clinical Oncology.

A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.

S. Chawla, M. Merchant, Shiraj Sen, 2020 .